Skip to main content
    M

    Myriad Genetics Inc (MYGN)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $4.35
    +0.20 (+4.82%)

    Market Cap: $396.95M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    69%(27/39)
    Avg Surprise
    -37.04%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.20
    Range$-0.27 - $-0.15
    8 analysts
    EPS RevisionsNo revisions (7d)
    0
    8
    30d
    EPS Estimate DriftChange to current
    90d ago$0.07-378.9%
    60d ago$-0.16-22.4%
    30d ago$-0.21+6.7%
    7d ago$-0.200.0%
    Current$-0.20
    Revenue Consensus
    $191M
    Range$189M - $193M
    8 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.42
    Range$-0.57 - $-0.26
    9 analysts
    Revenue Consensus
    $178M
    Range$173M - $184M
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.42---
    Sep 26EST
    		-$-0.20---
    Jun 26
    Reported Jul 30
    		$-0.33$-0.08-312.50%Miss-760.0%
    Mar 26
    Reported May 5
    		$-0.09$-0.07-28.57%Miss-200.0%
    Dec 25
    Reported Feb 23
    		$0.04$-0.02+332.56%Beat+33.3%
    Sep 25
    Reported Nov 3
    		$-0.29$-0.01-2800.00%Miss-583.3%
    Jun 25
    Reported Aug 5
    		$0.05$-0.01+600.00%Beat+0.0%
    Mar 25
    Reported May 6
    		$-0.03$-0.05+40.00%Beat-200.0%
    Dec 24
    Reported Feb 24
    		$0.03$0.03-0.99%Miss-25.0%
    Sep 24
    Reported Nov 7
    		$0.06$0.02+200.00%Beat+300.0%
    Jun 24
    Reported Aug 6
    		$0.05$-0.01+600.00%Beat+162.5%
    Mar 24
    Reported May 7
    		$-0.01N/A+90.91%Beat+95.2%
    Dec 23
    Reported Feb 27
    		$0.04$0.01+300.00%Beat+133.3%
    Sep 23
    Reported Nov 6
    		$-0.03N/A+62.50%Beat+84.2%
    Jun 23
    Reported Aug 3
    		$-0.08$-0.09+11.11%Beat-300.0%
    Mar 23
    Reported May 3
    		$-0.21$-0.19-10.53%Miss-600.0%
    Dec 22
    Reported Feb 28
    		$-0.12$-0.16+25.00%Beat-500.0%
    Sep 22
    Reported Nov 1
    		$-0.19$-0.08-137.50%Miss-850.0%
    Jun 22
    Reported Aug 4
    		$0.04$0.02+100.00%Beat-66.7%
    Mar 22
    Reported May 5
    		$-0.03N/A+66.67%Beat+50.0%
    Dec 21
    Reported Feb 24
    		$-0.02$-0.02+0.00%Beat+83.3%
    Sep 21
    Reported Nov 2
    		$-0.02$-0.01-100.00%Miss+86.7%
    Jun 21
    Reported Aug 3
    		$0.12$-0.10+220.00%Beat+138.7%
    Mar 21
    Reported May 3
    		$-0.06N/A+60.00%Beat+25.0%
    Dec 20
    Reported Feb 23
    		$-0.12$-0.12+0.00%Beat-152.2%
    Sep 20
    Reported Nov 9
    		$-0.15$-0.30+50.00%Beat-287.5%
    Jun 20
    Reported Aug 13
    		$-0.31$-0.47+34.04%Beat-175.6%
    Mar 20
    Reported May 5
    		$-0.08$0.01-900.00%Miss-117.4%
    Dec 19
    Reported Feb 6
    		$0.23$0.29-20.69%Miss-39.5%
    Sep 19
    Reported Nov 4
    		$0.08N/A-74.19%Miss-81.4%
    Jun 19
    Reported Aug 13
    		$0.41$0.48-14.58%Miss+7.9%
    Mar 19
    Reported May 7
    		$0.46$0.43+6.98%Beat+48.4%
    Dec 18
    Reported Feb 5
    		$0.38$0.39-2.56%Miss+22.6%
    Sep 18
    Reported Nov 6
    		$0.43$0.31+38.71%Beat+65.4%
    Jun 18
    Reported Aug 21
    		$0.38$0.33+15.15%Beat+26.7%
    Mar 18
    Reported May 8
    		$0.31$0.27+14.81%Beat+14.8%
    Dec 17
    Reported Feb 6
    		$0.31$0.24+29.17%Beat+19.2%
    Sep 17
    Reported Nov 7
    		$0.26$0.21+23.81%Beat-
    Jun 17
    Reported Aug 8
    		$0.30$0.26+15.38%Beat-
    Mar 17
    Reported May 2
    		$0.27$0.24+12.50%Beat-
    Dec 16
    Reported Feb 7
    		$0.26$0.24+8.33%Beat-

    Dividends

    Dividend Metrics

    Forward Yield0.00%
    Forward Annual Dividend$0.00
    Payout Ratio0.00%
    No dividend payments in the selected period.

    Key Metrics

    Valuation
    P/E Ratio-6.49EV/EBITDAN/A
    Price/FCF-56.49xFCF Yield-1.77%
    Profitability
    Profit Margin-14.00%Operating Margin-20.40%
    ROE-32.50%ROIC-23.03%
    Financial Health
    Debt/Equity0.40xInterest Coverage-5.96x
    Current Ratio2.21xQuick Ratio1.98x
    Trading Statistics
    Beta1.64Avg Volume1.90M
    52-Week High$8.5052-Week Low$2.74

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.30
    SMA 20$4.20
    SMA 50$3.65
    SMA 200$4.64
    EMA 10$4.23
    EMA 20$4.14
    EMA 50$4.05
    EMA 200$4.71

    MACD

    Line: 0.13Signal: 0.15Hist: -0.02

    ADX

    ADX: 34.4+DI: 26.3-DI: 12.7

    Aroon & PSAR

    Aroon Up72.0
    Aroon DownN/A
    PSAR$4.66

    Bollinger Bands

    Upper Band$4.55
    Lower Band$3.86
    %B Position1639%(Upper)
    Band Width0.71

    RSI (14-Day)

    Neutral
    58.3

    Momentum Oscillators

    Stoch %K22.1
    Stoch %D23.5
    Williams %R-60.6
    ROC (10d)7.1%
    Momentum0.29
    CCI (20d)48.9
    MFI (14d)58.1

    Volatility Measures

    ATR (14d)$0.26(5.9%)
    StdDev (20d)0.17
    Hist Vol66.1%(High)

    Volume Flow

    VWAP$4.29
    OBV-1.4M
    AD Line-33.1M
    CMF (20d)0.006

    Volume Metrics

    Avg Vol (20d)1.8M
    Vol Ratio0.6x
    VWMA (20d)$4.19

    Pivot Points

    R3$4.52
    R2$4.40
    R1$4.28
    Pivot Point$4.16
    S1$4.03
    S2$3.91
    S3$3.79

    Advanced Oscillators

    TSI15.64
    Ultimate Osc54.7
    KST239.21

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$190.70M$200.40M$209.80M$205.70M$213.10M$195.90M$210.60M$213.30M$211.50M$202.20M$196.60M$191.90M
    Cost of Revenue$63.70M$62.80M$63.00M$61.90M$61.30M$61.70M$59.70M$63.50M$64.40M$64.60M$61.60M$57.60M
    Gross Profit$127.00M$137.60M$146.80M$143.80M$151.80M$134.20M$150.90M$149.80M$147.10M$137.60M$135.00M$134.30M
    Operating Expenses$165.90M$168.30M$152.50M$167.10M$481.00M$163.20M$190.00M$169.80M$183.60M$165.50M$166.40M$194.40M
    R&D$25.00M$27.10M$25.50M$28.20M$25.60M$27.50M$32.90M$28.50M$27.10M$24.90M$21.00M$24.00M
    SG&A$57.80M$62.20M$55.60M$67.90M$66.80M$66.50M$63.40M$69.20M$72.10M$71.20M$-144,800,000$136.10M
    Operating Income$-38,900,000$-30,700,000$-5,700,000$-23,300,000$-329,200,000$-29,000,000$-39,100,000$-20,000,000$-36,500,000$-27,900,000$-31,400,000$-60,100,000
    Interest Income$400,000$700,000$800,000$500,000$200,000$300,000$300,000$400,000$400,000$600,000$700,000$600,000
    Interest Expense$4.10M$4.10M$4.40M$3.80M$1.50M$800,000$700,000$800,000$800,000$500,000$900,000$1.00M
    Income Before Tax$-42,600,000$-34,100,000$-8,900,000$-26,200,000$-330,600,000$-29,400,000$-39,200,000$-21,200,000$-37,200,000$-25,900,000$-32,300,000$-61,200,000
    Income Tax Expense$600,000$0$-1,000,000$1.20M$-100,000$-29,300,000$3.30M$900,000$-500,000$100,000$-1,100,000$100,000
    Net Income$-43,200,000$-34,100,000$-7,900,000$-27,400,000$-330,500,000$-100,000$-42,500,000$-22,100,000$-36,700,000$-26,000,000$-31,200,000$-61,300,000
    EBITDA$-26,400,000$-18,200,000$7.30M$-10,300,000$-315,200,000$-14,500,000$-24,000,000$-5,200,000$-21,700,000$-10,300,000$-17,000,000$-46,700,000
    EBIT$-38,900,000$-30,700,000$-5,300,000$-22,900,000$-329,300,000$-28,900,000$-38,800,000$-20,800,000$-36,800,000$-26,000,000$-32,100,000$-60,800,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MYGN

    Government Contracts

    Gov Obligations (TTM)
    -$60344
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    1
    New Awards (TTM)
    0
    Avg Remaining Term
    N/A

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Myriad Genetics to report Q3FY26 results on November 4, 2026

    Myriad Genetics will release its third-quarter 2026 financial results on November 4, 2026, after market close, followed by a conference call at 4:30 pm ET. The call will provide a financial overview and business update...

    scanx.trade•10/15/26•Neutral

    What Myriad Genetics Doubters Saw Before The Drop

    Myriad Genetics reported a significant revenue drop in Q2 2026 and cut full-year guidance, challenging optimistic growth narratives despite a narrowed net loss. Investors previously weighed bullish views of genomics...

    Simply Wall Street•10/15/26•Neutral

    Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026

    Myriad Genetics, Inc. will announce its third-quarter 2026 financial results on November 4, 2026, after market close. A conference call will follow at 4:30 p.m. ET...

    Yahoo Finance•10/15/26•Neutral

    What Myriad Genetics Doubters Saw Before The Drop

    Investors who were cautious about Myriad Genetics a year ago, despite bullish narratives around genomics and AI, avoided a significant loss. The company's recent Q2 2026 results, showing lower revenue and cut guidance...

    Yahoo Finance•10/14/26•Somewhat-Bearish

    SOPHiA GENETICS, Myriad Genetics and AstraZeneca Collaborate to Advance Precision Oncology in Prostate Cancer

    SOPHiA GENETICS, Myriad Genetics, and AstraZeneca are collaborating to advance precision oncology in prostate cancer. The partnership focuses on validating and expanding access to a novel prostate cancer-specific genomic...

    BioPharma APAC•10/12/26•Bullish

    MYGN Valuation and Fair Value

    P/E
    -6.5x
    Forward P/E
    54.0x
    P/FCF
    -56.5x
    PEG
    1.4x
    P/B
    1.4x
    See GNG's fair value

    MYGN Profitability: Margins, ROIC and FCF

    Gross margin
    68.8%
    Operating margin
    -20.4%
    Net margin
    -14.0%
    ROIC
    -23.0%
    ROE
    -32.5%
    FCF margin
    -0.9%
    FCF yield
    -1.8%

    MYGN Competitors

    CompanyTicker
    Avita Medical LtdRCEL
    ARS Pharmaceuticals, IncSPRY
    Rezolute IncRZLT
    TruBridge Inc.TBRG
    Tectonic Therapeutic, Inc.TECX
    I-MabIMAB
    DiaMedica Therapeutics IncDMAC
    Strata Critical Medical, Inc.SRTA

    Sector: Healthcare

    MYGN Analyst Ratings

    Consensus
    Hold
    Analysts
    9
    Strong Buy
    0
    Buy
    1
    Hold
    5
    Sell
    1
    Strong Sell
    2

    MYGN Bull Case vs Bear Case

    Bear case

    • MYGN has a -14.0% net profit margin.
    • MYGN's quarterly revenue changed -10.5% year over year.
    • 33.3% of MYGN's analyst ratings are Sell or Strong Sell.

    MYGN Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -246.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.20
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 8 down

    MYGN Dividend

    Forward yield
    0.0%
    Payout ratio
    0.0%

    Frequently Asked Questions About MYGN

    Does MYGN pay dividends?

    Myriad Genetics Inc (MYGN) has a dividend payment track record. See the MYGN dividend history page for its current payment status, TTM yield, and recorded payments.

    What is MYGN's market cap?

    Myriad Genetics Inc (MYGN) has a market capitalization of $396.95M with a current stock price of $4.35.

    Related stocks

    Sector: Healthcare

    All stocks starting with M

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In